Where Are The Biosimilars?
This article was originally published in RPM Report
Executive Summary
An abbreviated pathway for follow-on biologics was one of the biggest issues for biotech investors in the legislative debate over health care reform. Two years after enactment, FDA is still waiting for the first application.
You may also be interested in...
Words Of Wisdom For Biosimilar Developers
FDA has learned a lot from its biosimilar meetings and sponsor discussions so far – including the areas sponsors struggle with and how others might improve their understanding going forward.
Biosimilars: Is The Game About To Change In Europe?
Seven years since the first biosimilar hit the European market, these almost-copies have clearly disappointed. Now, though, momentum is building. Attitudes and regulations are slowly changing as cost-pressures continue – with implications for the U.S. And they’re doing so just as regulators review biosimilar Remicade, the first of a potentially far more lucrative set of copycat biologics.
Much “Ado” About Biosimilars
The approval of Kadcyla gives Roche/Genentech yet another new breakthrough cancer therapy in the US. It also offers some clues about the future of biosimilars at FDA.